Sionna Therapeutics, Inc.’s (NASDAQ:SION) Quiet Period To Expire Tomorrow

Sionna Therapeutics’ (NASDAQ:SION) quiet period is set to expire on Wednesday, March 19th. Sionna Therapeutics had issued 10,588,233 shares in its initial public offering on February 7th. The total size of the offering was $190,588,194 based on an initial share price of $18.00. During the company’s quiet period, underwriters and any insiders involved in the IPO are restricted from issuing any research reports or earnings estimates for the company because of SEC regulations. Following the expiration of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Analysts Set New Price Targets

SION has been the subject of several analyst reports. Guggenheim started coverage on Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $45.00 target price for the company. TD Cowen began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating for the company. Finally, Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a research report on Tuesday, March 4th. They set a “buy” rating and a $32.00 price target on the stock.

Sionna Therapeutics Price Performance

SION opened at $14.89 on Tuesday. Sionna Therapeutics has a 1-year low of $13.20 and a 1-year high of $25.19.

Sionna Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.